Aktienanalyse zu Dexcom Inc (DXCM)DXCMDexcom Inc

DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. It enables people to take control of health through innovative biosensing technology. The G7 is an integrated continuous glucose monitoring system. Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes. The G7 and G7 15 Day includes finger stick elimination, continuous glucose readings and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Dexcom Inc (DXCM) is a good buy right now, trading at $86.04 with a forward P/E of 28.25, indicating potential for growth. The company's gross margin stands at 63.44%, reflecting strong profitability. Analyst targets suggest a potential upside, with BTIG raising their target to $96 and Barclays initiating at $115. The main risk is the recent 20-day change of -3.70%, indicating some volatility, but the overall long-term outlook remains positive.

18 analysts cover DXCM: 11 rate it Buy, 7 Hold and 0 Sell. The average price target is 82.54.